The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06012084
Recruitment Status : Recruiting
First Posted : August 25, 2023
Last Update Posted : January 3, 2024
Sponsor:
Collaborators:
Saskatchewan Health Authority - Regina Area
Provincial Health Services Authority
Information provided by (Responsible Party):
University of Regina

Brief Summary:

The goal of the clinical trial is to test whether a mental health program that is delivered through the Internet works well for healthy children and adolescents with siblings with cystic fibrosis (CF). The main questions it aims to answer are:

  • Does the program improve the mental health and quality of life of healthy siblings?
  • Does the program improve the relationship between healthy children and adolescents and their sibling with CF?
  • Does the program help healthy siblings learn about CF?

Participants will:

  • Fill out an online survey asking questions about their family and mental health before the program
  • Complete the online mental health program over five weeks
  • Fill out a weekly question asking about their mood for 10 weeks
  • Fill out an online survey asking questions about their family and mental health after the program

Healthy children and adolescents with siblings with CF will be compared against themselves. Researchers will compare participants scores before starting the program with their scores during and after completing the program. Researchers hope to develop a program that improves mental health, quality of life, sibling relationships, and knowledge about CF.


Condition or disease Intervention/treatment Phase
Cystic Fibrosis Siblings Mental Health Internet-based Intervention Behavioral: Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single-case experimental design (SCED), across-participant AB design. Randomized phase-order will be used in that the start point of the intervention phase will be randomized across participants.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Development and Evaluation of an Internet-delivered Mental Health Prevention Program for Healthy Child Siblings of Individuals With Cystic Fibrosis
Actual Study Start Date : September 6, 2023
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : April 2024


Arm Intervention/treatment
Experimental: iCF-PWR Intervention

Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program is comprised of five text/voice-delivered, animated, interactive modules. The pathways are comprised of the same modules that take approximately 15 to 20 minutes to complete. Modules are comprised of web pages and/or screens with numerous illustrations and interactive components. Written module content will be presented verbally as well as in text format.

The program modules include: (1) What is CF? (i.e., physiological explanation of CF, prevalence rate); (2) How does my sibling with CF stay healthy? (i.e., review of medication, nutrition, physiotherapy treatment, and why treatment is important); (3) How does CF affect me?; (4) Mental health awareness (i.e., introduction to cognitive behaviour model of emotions-thoughts, feelings, bodily sensations, and behaviours); and (5) Strategies (i.e., ways to challenge unhelpful thoughts, talking about emotions, relaxation).

Behavioral: Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program
The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.




Primary Outcome Measures :
  1. Change in Mood and Anxiety Rating [ Time Frame: 10 Weeks ]
    Single ratings of self-reported mood and anxiety will be completed ten times over the course of the study. One question will assess mood and one question will assess anxiety using a 3-point Likert scale (0 = none of the time; 1 = some of the time; 2 = a lot of the time) to indicate the frequency of the symptom that day. Ratings will be completed prior to beginning the program (baseline - phase A) and during completion of the program (intervention - phase B). The number of ratings in each phase will vary based on the participant and be distributed equally across the 5-week periods with a minimum of three ratings per phase (i.e., during baseline or intervention).

  2. Change from Baseline in the State-Trait Anxiety Inventory for Children (STAI-C) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The STAI-C measures general anxiety in children on a continuous scale with items being rated on a 3-point Likert scale reflecting the frequency of anxiety symptom. Total scores can range from a minimum score of 20 to a maximum score of 60.

  3. Change from Baseline in the Children's Depression Inventory-2 (CDI-2) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The CDI-2 measures cognitive, affective, and behavioural symptoms of depression in children and adolescents on a continuous scale. Each item is rated on a 3-point Likert scale ranging from 0 (absence of symptom) to 2 (definite symptom). Total raw scores are converted into T-scores with a score of 65 being indicative clinically significant depressive symptoms.

  4. Change from Baseline in the Childhood Illness Attitudes Scale (CIAS) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    the CIAS assesses fears, beliefs, and attitudes that are associated with health anxiety and abnormal illness behaviour in school children on a continuous scale. Items are rated on a 3-point Likert scale with total scores range from 29 to 87 with higher scores reflecting higher levels of health anxiety associated behaviours.

  5. Change from Baseline in the Childhood Anxiety Sensitivity Index (CASI) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The CASI measures fear of anxiety-related symptoms in school children on a continuous scale. Each item is rated on a 3-point Likert scale (1 = none; 2 = some; 3 = a lot) with total scores ranging from 18 to 54 and higher scores reflecting higher levels of anxiety sensitivity.

  6. Change from Baseline in the Intolerance of Uncertainty Scale-Revised (IUS-R) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The IUS-R measures intolerance of uncertainty in children on a continuous scale. Items are rated on a 5-point Likert scale ranging from 1 (not at all like me) to 5 (entirely like me). Total scores range from 12 to 60 with higher scores indicating higher levels of IU.

  7. Change from Baseline in the Pediatric Quality of Life Inventory (PedsQL-4.0) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The PedsQL-4.0 measures health-related quality of life in healthy and acute and chronically ill children and adolescents on a continuous scale. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (almost always). The PedsQL-4.0 is comprised of four generic core scales that encompass physical functioning, emotional functioning, social functioning, and school functioning.

  8. Change from Baseline in the Sibling Relationship Questionnaire-Revised (SRQ-R) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The SRQ-Rdesigned to assess children's perceptions of their siblings in areas of Closeness/Intimacy, Power, Conflict, and Rivalry. On a 5-point Likert scale ranging from 1 (hardly at all) to 5 (extremely much) children are asked to rate how well a characteristic describes their relationship with their sibling. Higher scores on each of the scales and factors indicate greater levels of the specified relationship quality in the sibling relationship.

  9. Change from Baseline in the Disease Knowledge Questionnaire [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The measure was constructed to assess CF disease knowledge as it related to the iCF-PWR content. It is comprised of 13 items rated on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree). Higher scores indicate greater CF disease knowledge.


Secondary Outcome Measures :
  1. Change from Baseline in the Children's Depression Inventory-2 - Parent Report (CDI-2 P) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The CDI-2 P assesses a parent's observation of their child's or adolescent's cognitive, affective, and behavioural symptoms of depression. Each item is rated on a 4-point Likert scale ranging from 0 (not at all) to 2 (much or most of the time). Total raw scores are converted into T-scores with a score of 65 being indicative clinically significant depressive symptoms.

  2. Change from Baseline in the State-Trait Anxiety Inventory - Parent Version (STAI-P) [ Time Frame: Baseline and Week 10 (post-intervention) ]
    The STAI-P assesses state anxiety (i.e., at this present moment) in school children with and without physical symptoms. Items are rated on a 4-point Likert scale reflecting the frequency the anxiety symptom occurs (1 = not at all; 2 = sometimes; 3 = moderately; 4 = very much so). Total scores for the subscales can range from a minimum score of 20 to a maximum score of 80.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • between the ages of 8 and 12
  • have a child or adolescent sibling with cystic fibrosis
  • able to speak and read English

Exclusion Criteria:

  • have a severe cognitive impairment or a major comorbid medical or psychiatric illness, as this may have interfered with their ability to participate in the program and evaluation process required for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06012084


Contacts
Layout table for location contacts
Contact: Shelby M Shivak, M.A. 3065506874 shivak3s@uregina.ca

Locations
Layout table for location information
Canada, Saskatchewan
University of Regina Recruiting
Regina, Saskatchewan, Canada, S4S 0A2
Contact: Kristi D Wright, Ph.D       Kristi.Wright@uregina.ca   
Sponsors and Collaborators
University of Regina
Saskatchewan Health Authority - Regina Area
Provincial Health Services Authority
Investigators
Layout table for investigator information
Study Director: Kristi D Wright, Ph.D University of Regina
Publications:
Giallo R, Gavidia-Payne, S. Evaluation of a family-based intervention for siblings of children with disability or chronic illness. Australian e-Journal for the Advancement of Mental Health. 2008; 7(22).

Layout table for additonal information
Responsible Party: University of Regina
ClinicalTrials.gov Identifier: NCT06012084    
Other Study ID Numbers: 2021-123
First Posted: August 25, 2023    Key Record Dates
Last Update Posted: January 3, 2024
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Regina:
cystic fibrosis
siblings
mental health
child
adolescent
sibling relations
Internet-based intervention
anxiety
depression
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases